GO
Loading...

Enter multiple symbols separated by commas

GlaxoSmithKline PLC

More

  • What matters to markets this week Monday, 4 May 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • Siemens unit in China bribery probe - report Sunday, 3 May 2015 | 5:42 AM ET
  • The investigation, which has not previously been reported, follows a wide-reaching probe into the pharmaceutical industry in China that last year saw GlaxoSmithKline Plc fined nearly $500 million for bribing officials to push its medicine sales. "We are not aware of any situation that conforms to what you describe," said Germany- based spokesman Matthias...

  • Jobs report is big but watch out for Europe Friday, 1 May 2015 | 7:21 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • *Cash return was planned after Novartis asset swap deal. Instead, Britain's biggest drugmaker could use cash flowing in from its far-reaching asset swap deal with Novartis to support its dividend, according to analysts at Goldman Sachs and Berenberg Bank. GSK said last year it intended to return 4 billion pounds to shareholders in 2015 through a so-called B...

  • LONDON, April 28- An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline. Goldman Sachs analysts said in a report on Tuesday that efficacy across age groups could give HZ/su a meaningful edge over Zostavax,...

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • *Global nutraceutical market seen at $280 bln by 2018. LONDON, April 21- A boom in "nutraceuticals"- food and drinks with potential health benefits- is paving the way for a rush of deals, as food and drug companies compete to dominate a market expected to be worth $280 billion by 2018.. "The space is ripe for M&A and I think you are going to see more," added Jeremy Johnson,...

  • This country is becoming a force in 'fintech' Friday, 17 Apr 2015 | 2:34 AM ET
    London's Old Street roundabout, dubbed "Silicon Roundabout"

    Investment in technology that provides financial services has more than tripled in the region, giving its economy a much-needed boost.

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Tuesday, 31 Mar 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, March 30- GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson& Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share. The settlement was disclosed during a hearing in Manhattan federal court on Monday in which two Johnson& Johnson units were expected to ask a judge to block Glaxo from making...

  • J&J, Glaxo settle U.S. lawsuit over allergy ads Monday, 30 Mar 2015 | 6:07 PM ET

    NEW YORK, March 30- GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson& Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share. The settlement was disclosed during a hearing in Manhattan federal court on Monday in which two Johnson& Johnson units were expected to ask a judge to block Glaxo from making...

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • March 19- GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma, but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. Glaxo licensed the product from...

  • Box nabs US government IT executive Thursday, 19 Mar 2015 | 1:08 PM ET
    Aaron Levie, CEO of Box, speaks during the BoxWorks 'How Tomorrow Works' event in San Francisco, California.

    The former CIO of the General Services Administration will lead Box's efforts to lure government agencies to move to its cloud platform.

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...